The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
CASE REPORT: Troglitazone-Induced Fulminant Hepatic Failure
Abstract
The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury. Thus, troglitazone should be prescribed with caution and should not be used as a first-line agent in the treatment of type II DM when potentially less toxic alternatives are available. It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone. Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity. If troglitazone is used, frequent monitoring of serum aminotransferases and symptoms is mandatory. However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable. Thus, the value of close monitoring and when, if ever, it is safe to stop such monitoring are currently unclear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, only pioglitazone is available; troglitazone was withdrawn from the market in 2000 and rosiglitazone was withdrawn in 2010 due to liver toxicity, drug-induced hepatitis352, 353, 354 and the increased risk of cardiovascular events, respectively.355”
From Pancreatic regulation of glucose homeostasis. (2016) · cites this paper as [352]
Citations
Cites
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B. H., Beerdsen, P., Joyce, M., & Olefsky, J. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 913
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 443
Effect of Troglitazone in Insulin-Treated Patients with Type II Diabetes Mellitus
Schwartz, S. L., Raskin, P., Fonseca, V. A., & Graveline, J. F. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381302 · Cited by 327
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 229
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Zimmerman, H. J. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70097-0 · Cited by 186
An Autopsy Case of Troglitazone-Induced Fulminant Hepatitis
Shibuya, A., Watanabe, M., Fujita, Y., Saigenji, K., Kuwao, S., Takahashi, H., & Takeuchi, H. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2140 · Cited by 104
Fatal Hepatotoxicity Associated with Troglitazone
Vella, A. V., de Groen, P. C., & Dinneen, S. F. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-12-199812150-00032 · Cited by 76
10.1016/b978-0-323-44355-5.00011-3
(2000) · Time to knit · doi:10.1016/b978-0-323-44355-5.00011-3 · Cited by 1
Flagged first, then by citations
Research works printed but not linked: 2
- Farrell GC: Liver disease caused by drugs, anesthetics, and toxins. In Gastrointestinal Disease. M Feldman, BF Scharschmidt, MH Sleisenger (eds). Philadelphia, WB Saunders, 1998, pp 1221-1252
- Parke-Davis: Prescribing information for Rezulin. Parke-Davis, Morris Plains, New Jersey, July 1998
Cited by
Sorted by citations
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Self-citationLee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Self-citationOral Antihyperglycemic Therapy for Type 2 Diabetes
Inzucchi, S. E. (2002) · JAMA · doi:10.1001/jama.287.3.360 · Cited by 1,063
Pancreatic regulation of glucose homeostasis.
Röder, P. V., Wu, B., Liu, Y., & Han, W. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.6 · Cited by 985
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy‐Wenzig, E., Blunder, M., Liu, X., Malainer, C., Blažević, T., Schwaiger, S., Rollinger, J. M., Heiß, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 616
Metadata
- Authors
- Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., & Bass, N. M.
- Affiliations
- University of Pittsburgh (US)
- Venue
- Digestive Diseases and Sciences
- Published
- 2000-03
- Volume
- 45
- Issue
- 3
- Pages
- 549-553
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2288490027
- Cited by
- 111
- References
- 10
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 4 · 2021: 1 · 2019: 1 · 2017: 2 · 2016: 3 · 2015: 1 · 2014: 2 · 2013: 8 · 2012: 7
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R03 DK5287-01)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- troglitazone, acute liver failure, drug-induced liver injury, hepatotoxicity, thiazolidinediones, type 2 diabetes, idiosyncratic hepatotoxicity, adverse drug reactions
- MeSH terms
- Troglitazone, Chromans, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Liver, Middle Aged, Thiazoles, Liver Failure, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
